Overview

Atomoxetine in Patients With Tourette's Syndrome

Status:
Not yet recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this pilot study is to evaluate the effects of Atomoxetine, a selective noradrenaline reuptake inhibitor, on impulsivity in patients with Tourette's syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Poitiers University Hospital

Treatments:

Atomoxetine Hydrochloride